Wilson Roa

Contact

Faculty of Medicine & Dentistry - Oncology Dept
Email
wroa@ualberta.ca
Phone
(780) 432-8783
Address
Cross Cancer Institute
11560 University Avenue
Edmonton AB
T6G 1Z2

Overview

Area of Study / Keywords


About

As an academic oncologist, Dr. Roa contributes to research, teaching, administration and patient care.
 
Clinical Service
Despite the various involvements, the day-to-day care for cancer patients takes the lion’s share of Dr. Roa’s committed time as a physician. 

Research

Dr. Roa is involved in the translational research of 1) nano-carrier platform for chemotherapeutics and radiation therapeutics; 2) image-guided adaptive radiotherapy with gated immobilization, functional targeting and/or intensity modulation; 3) early-phase clinical trial involving cytokines and miRNA targets.  These works are performed in collaboration with colleagues from departments of chemistry, engineering, medicine, pathology, pharmacy, physics, radiology, surgery and experimental oncology.  Over a dozen of peer-reviewed clinical trials in the fields of neuro-oncology and lung cancer are performed at any point in time at Cross Cancer Institute, ranging from in-house to international studies.  For example, a phase III international randomized radiotherapy study in older patients with a common high-grade glioma has been administered under the auspice of the institute department.  The study will further improve clinical practice.
 
Dr. Roa contributes to scientific steering committees of research groups and consortiums such as the Radiation Therapy and Oncology Group (RTOG), and to funding reviews as an invited panel member for cancer agencies such as the Ontario Cancer Research Network and the Canadian Association of Radiation Oncology.  He participates also as an invited peer-reviewer for scientific journals such as the American Journal of Clinical Oncology, Radiation Oncology, Biology & Physics, and Expert Opinion on Investigational Drugs.

Teaching

Dr. Roa plays the role of teacher, supervisor and/or mentor for post-doctoral fellows, residents, research trainees, graduate and medical students.  The post-graduate education program at University of Alberta has become a most sought after graduate program, and a residency training accredited by the Royal College of Physicians and Surgeons of Canada.

Featured Publications

Wang M.H., Roa W., Wachowicz K., Yahya A., Murtha A., Amanie J., Chainey J., Quon H., Ghosh S., Patel S.

Anticancer Research. 2022 May; 42 (5):2665-2673 10.21873/anticanres.15744


Song A.J., Ding K., Alnahhas I., Laperriere N.J., Perry J., Mason W.P., Winch C., O'callaghan C.J., Menten J.J., Brandes A.A., Phillips C., Fay M.F., Nishikawa R., Osoba D., Cairncross J.G., Roa W., Wick W., Shi W.

Neuro-Oncology Advances. 2022 January; 4 (1):vdac011 10.1093/noajnl/vdac011


A novel composite biomarker panel for detection of early stage non-small cell lung cancer.

CARO (Annual Conference of Canadian Association of Radiation Oncology). 2021 October;


A randomized trial of short-course versus conventional radiotherapy with concomitant and adjuvant temozolomide in patients 18 to 70 years of age with glioblastoma.

ASTRO (Annual Conference of American Society of Radiation Oncology). 2021 October;


Song A.J., Ding K., Alnahhas I., Laperriere N.J., Perry J., Mason W.P., Winch C., O'callaghan C.J., Menten J.J., Brandes A.A., Phillips C., Fay M.F., Nishikawa R., Osoba D., Cairncross J.G., Roa W., Wick W., Shi W.

Neuro-Oncology Advances. 2021 October; 3 (1):vdab153 10.1093/noajnl/vdab153


Predictors of toxicity in a randomized study of hypofractionated vs. conventional radiotherapy for glioblastoma: Dosimetric analysis of organs at risk.

CARO (Annual Conference of Canadian Association of Radiation Oncology). 2021 October;


The use of proton pump inhibitors does not adversely influence pathological and clinical outcomes when used with Capecitabine in the neo-adjuvant chemo-radiation treatment of locally advanced rectal cancer.

CARO (Annual Conference of Canadian Association of Radiation Oncology). 2021 October;


Menon A., Abraham A.G., Mahfouz M., Thachuthara J.J., Usmani N., Warkentin H., Ghosh S., Nijjar T., Severin D., Tankel K., Paulson K., Mulder K., Roa W., Joseph K.

American Journal of Clinical Oncology: Cancer Clinical Trials. 2021 July; Online ahead of print 10.1097/COC.0000000000000850


Tsakiridis T., Pond G.R., Wright J., Ellis P.M., Ahmed N., Abdulkarim B., Roa W., Robinson A., Swaminath A., Okawara G., Wierzbicki M., Valdes M., Levine M.

JAMA Oncology. 2021 July; Online ahead of print 10.1001/jamaoncol.2021.2328


Jamaluddin M.F., Abraham A.G., Menon G., Nakatsui T., Roa W.

Breast Journal. 2021 June; 27 (6):543-546 10.1111/tbj.14212


Abraham A.G., Roa W.

Journal of Thoracic Disease. 2021 May; 13 (5):3235-3245 10.21037/jtd-2019-rbmlc-01


Bedard E.L.R., Abraham A.G., Joy A.A., Ghosh S., Wang X., Lim A., Shao D., Loebenberg R., Roa W.H.

Clinical and investigative medicine. Medecine clinique et experimentale. 2021 March; 44 (1):E15-E24 10.25011/cim.v44i1.36016


Wu H.H., Wang B., Armstrong S.R., Abuetabh Y., Leng S., Roa W.H.Y., Atfi A., Marchese A., Wilson B., Sergi C., Flores E.R., Eisenstat D.D., Leng R.P.

Nucleic Acids Research. 2021 March; 49 (5):2740-2758 10.1093/nar/gkab081


Threshold values of early metabolomic changes in 1H MRSI metabolomic metrics predictive for survival in patients with newly diagnosed high-grade glioma.

Neuro-Oncology. 2020 November;


Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.

2020 ASTRO Annual Meeting. 2020 October;